Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-Ibritumomab Tiuxetan with Allo-HCT for Relapsed B-cell Lymphoma
NCT00119392Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2004
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in B cell lymphoma, sponsored by Fred Hutchinson Cancer Center. Started Jun 2004; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT00119392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00119392.